Through genomic sequencing and analytics, Sacramento-based Personalis aims to make detection of cancer ever more precise and timely. In October 2023, the company launched early access to its NeXT Personal Dx test, which offers ultra-sensitive circulating tumor DNA (ctDNA) detection, enabling earlier detection of cancer recurrence and more detailed monitoring of treatment response.
NeXT Personal Dx is a whole-genome sequencing test that detects circulating tumor DNA molecules, finding previously hidden traces of residual cancer, while reporting on specific mutations that can help identify personalized treatments. Personalis also supports the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It is collaborating with Moderna to analyze patient tumor data for its individualized neoantigen-based cancer therapeutics, now in Phase 3 trials, and with AstraZeneca to explore ultra-sensitive residual disease detection for cancer.
In November 2023, it entered a partnership with Tempus Labs, an AI and precision medicine company, to commercialize the test for lung cancer, breast cancer, and immunotherapy monitoring. The company’s third quarter revenue of $18.2 million was up 23% over last year.
Explore the full 2024 list of Fast Company’s Most Innovative Companies, 606 organizations that are reshaping industries and culture. We’ve selected the firms making the biggest impact across 58 categories, including advertising, artificial intelligence, design, sustainability, and more.
Login to add comment
Other posts in this group
Since it launched two years ago, Spotify’s AI DJ has been a one-way experience. It curates old favorites and helps listeners discover new tracks based on past listening experience and what similar
Artificial intelligence might be the future of the workplace, but companies that are trying to get a head start on that future are running into all sorts of problems.
Klarna and Duloingo
Now that the “100 men vs. one gorilla” debate has been settled, a new question is circulati
The rideshare market has reached a crossroads. Autonomous vehicles are on the rise, driver unrest is mounting, and customers are questioning everything from pricing to trust and safety. In the mid
